Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- 5 questions with… cancer disparities researcher Monica Webb Hooper
- Biology’s Valerie Haywood presents at American Society of Plant Biologists annual conference
- Donate blood at Aug. 25 American Red Cross drive
- Law’s Erik M. Jensen gives his take on benefits of the Electoral College
- Law’s Jonathan Entin pens two chapters for new books, two articles for “The Federal Lawyer”